Tildrakizumab in Patients With Psoriasis: Three-Year Efficacy Results From reSURFACE 1 and reSURFACE 2 in Those With and Without Metabolic Syndrome
ByLebwohl MG, Leonardi C, Menter A, et al. Tildrakizumab efficacy by metabolic syndrome status in psoriasis: post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study. Poster presented at: 28th European Academy of Dermatology,Venereology Congress,October 9-13, 2019,Madrid, Spain.Gottlieb AB, Leonardi C, Mehta NN, et al. Tildrakizumab efficacy by metabolic syndrome status in psoriasis: post hoc analysis of 3-year data from the phase 3 reSURFACE 2 study. Poster presented at: 28th European Academy of Dermatology and Venereology Congress,Madrid, Spain.